Richard Nicoletti
34 works · 1,605 citations · h-index 7
Top works
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients
- MAP3K11/GDF15 axis is a critical driver of cancer cachexia
- Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
- Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss
- Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients.
- Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody
- Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia.
- 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
- Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride.
- Supplementary Figures S1-3 and Table S1 from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
- SP696ASSOCIATION OF THE NOVEL CACHEXIA MARKER “GROWTH DIFFERENTIATION FACTOR 15” (GDF15) WITH MORTALITY IN HEMODIALYSIS PATIENTS
- Supplementary Materials and Methods from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
- Population-based engineered tumor models as a platform for biomarker discovery in cancer
- Supplementary Materials and Methods, Figure Legends from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
- Supplementary Figures 1 - 4, Tables 1 - 2 from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
- Data from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
- Supplementary Materials and Methods from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
- Abstract B18: Variation in response to VEGFR inhibitor tivozanib in a unique population-based tumor model enables the development of a multigene response biomarker